Table 2. Association of QRS/QT interval associated SNPs with SCD.

Trait	Nearest Gene	Index SNP	Chr	Position	Coded/Non-coded Allele	Trait β	SCD OR (95% CI)	SCD P	Concordant Effect
QRS	TKT/CACNA1D/PRKCD	rs4687718	3	53,257,343	A/G	−0.63	1.27 (1.10–1.45)	0.0007	NO
QRS	C6orf204/SLC35F1/PLN/BRD7P3	§rs11153730	6	118,774,215	C/T	0.59	1.13 (1.02–1.25)	0.013	YES
QT	NOS1AP	rs12143842	1	160,300,514	T/C	2.88	1.16 (1.03–1.3)	0.010	YES
QT	PLN	§rs11970286	6	118,787,067	T/C	1.64	1.11 (1.01–1.22)	0.037	YES
QT	KCNQ1	rs12296050	11	2,445,918	T/C	1.44	0.85 (0.76–0.96)	0.014	NO

Chr, chromosome; OR, odds ratio; CI, confidence interval. Results are drawn from the SCD GWAS only (n = 1283 case, >20,000 controls). Trait beta estimates (β) are in milliseconds (ms). P-values are for a two-tailed test. Concordant Effect refers to whether the QRS/QT prolonging allele is associated with increased risk of SCD. Bold indicates significant after Bonferroni correction for the 49 SNPs tested. QRS results are drawn from [14] and QT results are drawn from the QTSCD study [13]. § These SNP represent the same genetic effect (r² = 0.91).